Oxaliplatin + 5-Fluorouracil/Leucovorin

DRUG3 trials

Sponsors

Sanofi, First Affiliated Hospital of Zhejiang University, Kaohsiung Medical University Chung-Ho Memorial Hospital

Conditions

Bile Duct CarcinomaBiliary Tract CancerCarcinoma, HepatocellularCholangiocarcinomaGC/GEJCGall Bladder Cancer

Phase 1

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

Not yet recruitingNCT07680569

Kaohsiung Medical University Chung-Ho Memorial HospitalGC/GEJC

Start: 2026-06-01End: 2027-12-01Target: 40Updated: 2026-07-02

Phase 2

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

RecruitingNCT07025174

First Affiliated Hospital of Zhejiang UniversityBile Duct Carcinoma, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2025-06-01End: 2027-12-31Target: 60Updated: 2025-06-17

Phase 3

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

CompletedNCT00471965

SanofiCarcinoma, Hepatocellular

Start: 2007-03-31End: 2010-03-31Updated: 2010-09-20

Related Papers

Comprehensive Consideration before the Decision-Making of the Systemic Treatment in Patients with Advanced Hepatocellular Carcinoma

Liver Cancer2019-10-166 citations

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

2014-09-1573 citations